We report a case of recurrent glioblastoma (GBM) harboring BRAF V600E alteration who initially responded to combined BRAF + MEK inhibition and subsequently developed treatment resistance by histological transformation to gliosarcoma and acquisition of oncogenic KRASG12Dand an NF1L1083R mutation. The gene discussed is MAP2K7; the disease is gliosarcoma.